En studie for å evaluere effekten og sikkerheten til Fenebrutinib sammenlignet med teriflunomid ved tilbakevendende multippel sklerose (RMS) (FENhance)
En fase III multisenter randomisert, dobbeltblind, dobbeltdummy, parallellgruppestudie for å evaluere effekten og sikkerheten til Fenebrutinib sammenlignet med teriflunomid hos voksne pasienter med residiverende multippel sklerose
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Buenos Aires, Argentina, C1424
- Centro de Especialidades Neurológicas y Rehabilitación - CENyR
-
Buenos Aires, Argentina, C1405BCH
- IME - Instituto Médico Especializado
-
Buenos Aires, Argentina, C1182ACA
- Neurologia Infantil Buenos Aires (NIBA)
-
C. A. B. A., Argentina, C1055AAF
- CIER
-
Rosario, Argentina, 2000
- Diagnostico Medico Oroño
-
San Juan, Argentina, J5400CEP
- Cer San Juan
-
San Miguel de Tucumán, Argentina, T4000AXL
- Centro de Investigaciones Médicas Tucuman
-
-
-
-
-
Santiago de los Caballeros, Den dominikanske republikk, 51000
- NeuroINC
-
Santo Domingo, Den dominikanske republikk, 10210
- Hospital Padre Billini
-
-
-
-
-
Helsinki, Finland, 00290
- Helsinki University Central Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233
- University of Alabama Birmingham
-
Homewood, Alabama, Forente stater, 35209
- Alabama Neurology Associates
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85032
- Center for Neurology and Spine - Phoenix - Hunt - PPDS
-
-
California
-
Carlsbad, California, Forente stater, 92011
- Profound Research, LLC
-
Irvine, California, Forente stater, 92697
- University of California Irvine
-
Pasadena, California, Forente stater, 91106
- Quantum Clinical Research, Inc
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado Denver
-
Denver, Colorado, Forente stater, 80209
- Mountain View Clinical Research
-
Fort Collins, Colorado, Forente stater, 80528
- Advanced Neurology of Colorado, LLC
-
-
Florida
-
Maitland, Florida, Forente stater, 32751
- Neurology Associates, PA; Research Department
-
-
Illinois
-
Highland Park, Illinois, Forente stater, 60035
- NorthShore University HealthSystem
-
-
Indiana
-
Fort Wayne, Indiana, Forente stater, 46805
- Fort Wayne Neurological Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70810
- The NeuroMedical Center
-
Shreveport, Louisiana, Forente stater, 71103
- Ochsner LSU Health
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Johns Hopkins University School Of Medicine; Outpatient Center
-
-
Massachusetts
-
Worcester, Massachusetts, Forente stater, 01655
- University of Massachusetts Medical School
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48202
- Henry Ford Health System
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Teaneck, New Jersey, Forente stater, 07666
- Holy Name Hospital; Institute For Clinical Research
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87131
- University of New Mexico; MS Specialty Clinic
-
-
Ohio
-
Centerville, Ohio, Forente stater, 45459
- Miami Valley Hospital South; Dayton Physician's Office
-
Columbus, Ohio, Forente stater, 43214
- OhioHealth
-
Columbus, Ohio, Forente stater, 43235
- The Boster Center for Multiple Sclerosis a Singlepoint Healthcare Company
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Oklahoma Medical Research Foundation; MS Center of Excellence
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forente stater, 18015
- St. Luke's University Health network
-
-
South Carolina
-
Greenville, South Carolina, Forente stater, 29605
- Premier Neurology
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37920
- New Orleans Center for Clinical Research
-
-
Texas
-
Plano, Texas, Forente stater, 75024
- North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic
-
Sherman, Texas, Forente stater, 75092
- Texas Institute for Neurological Disorders
-
-
Virginia
-
Vienna, Virginia, Forente stater, 22182
- Multiple Sclerosis Center of Greater Washington
-
-
Washington
-
Kirkland, Washington, Forente stater, 98034
- Evergreen MS Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53215
- Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders
-
-
-
-
-
Tbilisi, Georgia, 0179
- Khechinashvili University Hospital
-
Tbilisi, Georgia, 0114
- New Hospitals
-
Tbilisi, Georgia, 0114
- Pineo Medical Ecosystem
-
Tbilisi, Georgia, 0160
- MediClab Georgia
-
Tbilisi, Georgia, 0159
- St. Michael hospital
-
-
-
-
-
Hong Kong, Hong Kong
- Pamela Youde Nethersole Eastern Hospital
-
Shatin, New Territories, Hong Kong
- Prince of Wales Hospital
-
-
-
-
Apulia
-
Foggia, Apulia, Italia, 71100
- AO.U. Policlinico Riuniti Foggia
-
-
Campania
-
Naples, Campania, Italia, 80131
- AOU Seconda Università degli Studi
-
Naples, Campania, Italia, 80138
- AOU Policlinico - Università L. Vanvitelli
-
-
Emilia-Romagna
-
Parma, Emilia-Romagna, Italia, 43126
- A.O.U. di Parma
-
-
Lazio
-
Rome, Lazio, Italia, 00185
- Policlinico Umberto I
-
Rome, Lazio, Italia, 00189
- Azienda Ospedaliera Sant'Andrea
-
Rome, Lazio, Italia, 00133
- Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla
-
-
Lombardy
-
Bergamo, Lombardy, Italia, 24127
- ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla
-
Milan, Lombardy, Italia, 20132
- IRCCS Ospedale San Raffaele
-
-
Piedmont
-
Mondovì (CN), Piedmont, Italia, 12084
- Ospedale Regina Montis Regalis
-
-
Sicily
-
Catania, Sicily, Italia, 95123
- AOU Policlinico V. Emanuele - P.O G. Rodolico
-
-
Veneto
-
Padova, Veneto, Italia, 35128
- Azienda Ospedaliera di Padova
-
-
-
-
-
Nairobi, Kenya, 00100
- The Aga Khan University-Kenya.
-
-
-
-
-
Beijing, Kina
- Beijing Tiantan Hospital,Capital Medical University
-
Beijing, Kina, 100034
- Peking University First Hospital
-
Changchun, Kina, 130021
- the First Hospital of Jilin University
-
Changsha, Kina, 410008
- Xiangya Hospital Central South University
-
Chengdu, Kina, 610041
- West China Hospital, Sichuan University
-
Chongqing, Kina, 400016
- The First Affiliated Hospital, Chongqing Medical University
-
Guangzhou, Kina, 510080
- The First Affiliated Hospital of Sun Yat-sen University
-
Guangzhou, Kina, 510260
- The second Affiliated Hospital of Guangzhou Medical University
-
Guiyang, Kina
- The affiliated Hospital of Guiyang Medical College
-
Kunming, Kina, 650021
- The First People?s Hospital of Yunnan Province
-
Shijiazhuang, Kina, 05000
- The Second Hospital of Hebei Medical University
-
Suzhou, Kina, 215031
- The First Affiliated Hospital of Soochow University
-
Taiyuan, Kina
- 1st Affiliated Hospital of Shanxi Medical University
-
Tianjin, Kina, 300052
- Tianjin Medical University General Hospital
-
Wuhan, Kina, 430030
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
-
Xi'an, Kina
- Tangdu Hospital, The Fourth Military Medical University
-
Ürümqi, Kina, 830000
- Xinjiang People Hospital
-
-
-
-
Coahuila
-
Saltillo, Coahuila, Mexico, 25050
- Clinical Research Institute Saltillo
-
-
Mexico CITY (federal District)
-
Mexico City, Mexico CITY (federal District), Mexico, 03100
- Grupo Medico de Investigacion Clinica Multidisciplinaria
-
Mexico City, Mexico CITY (federal District), Mexico, 03100
- Health Pharma Professional Research
-
-
Sinaloa
-
Culiacán, Sinaloa, Mexico, 80020
- Neurociencias Estudios Clinicos S.C.
-
-
Tlaxcala
-
Mexico, Tlaxcala, Mexico, 06726
- Hospital General de Mexico
-
-
-
-
-
Sittard-Geleen, Nederland, 6162 BG
- Zuyderland Medisch Centrum - Sittard Geleen
-
-
-
-
-
Shtip, Nord-Makedonia, 2000
- Clinical Hospital Stip
-
Skopje, Nord-Makedonia, 1000
- PHO General City Hospital 8th September Center for dialysis
-
Skopje, Nord-Makedonia, 1000
- University Clinic for Neurology - Skopje
-
-
-
-
-
Bellavista, Peru, Callao 2
- Hospital IV Alberto Sabogal Sologuren
-
La Victoria, Lima, Peru, Lima 13
- Hospital Nacional Guillermo Almenara Irigoyen
-
Lima, Peru, Lima 29
- Hospital Maria Auxiliadora
-
Lima, Peru, 15018
- Hospital Nacional Dos de Mayo
-
Lima, Peru, Lima 01
- Clinica Internacional Sede Lima
-
Pueblo Libre, Peru, Lima 21
- Clinica Centenario Peruano Japonesa
-
-
-
-
-
?ory, Polen, 44-240
- ProNeuro Centrum Medyczne
-
Bydgoszcz, Polen, 85-796
- Neurocentrum Bydgoszcz sp. z o.o
-
Katowice, Polen, 40-568
- Care Clinic
-
Krosno, Polen, 38-400
- MT Medic Krosno
-
Lodz, Polen, 90-324
- Centrum Neurologii Krzysztof Selmaj
-
Lublin, Polen, 20-492
- Rodzinne Centrum Medyczne Lubimed.pl
-
Warsaw, Polen, 02-957
- Instytut Psychiatrii i Neurologii II Klinika Neurologiczna
-
Zabrze, Polen, 41-800
- IBISMED Wielospecjalistyczne Centrum Medyczne
-
-
-
-
-
Braga, Portugal, 4710-243
- Hospital de Braga
-
Coimbra, Portugal, 3000-075
- HUC
-
Lisbon, Portugal, 1500-650
- Hospital da Luz
-
Lisbon, Portugal, 1169-050
- Hospital Santo Antonio dos Capuchos
-
Porto, Portugal, 4200-319
- Hospital de Sao Joao
-
Porto, Portugal, 4099-001
- Hospital Geral de Santo Antonio
-
Santa Maria da Feira, Portugal, 4520-211
- Centro Hospitalar Entre o Douro e Vouga E.P.E. - Hospital de São Sebastião
-
-
-
-
-
Kirov, Russland, 610007
- Center of Cardiology and Neurology
-
Novosibirsk, Russland, 630007
- FSBIH Siberian Regional Medical Centre of FMBA of Russia
-
-
Bashkortostan Republic
-
Ufa, Bashkortostan Republic, Russland, 450005
- Republican clinical hospital named after G.G. Kuvatov
-
-
Sankt-Peterburg
-
Saint Petersburg, Sankt-Peterburg, Russland, 194291
- Leningrad Regional Clinical Hospital
-
Saint Petersburg, Sankt-Peterburg, Russland, 197022
- Pavlov State Medical Uni
-
-
Ulyanovsk Oblast
-
Ulyanovsk, Ulyanovsk Oblast, Russland, 432063
- Ulyanovsk Regional Clinical Hospital
-
-
-
-
-
Belgrade, Serbia, 11000
- University Clinical Center of Serbia
-
-
-
-
-
Barcelona, Spania, 08035
- Hospital Universitari Vall d'Hebron
-
Madrid, Spania, 28034
- Hospital Ramon y Cajal
-
Madrid, Spania, 28007
- Hospital General Universitario Gregorio Marañon
-
Madrid, Spania, 28040
- Fundacion Jimenez Diaz
-
Madrid, Spania, 28006
- Hospital Universitario de la Princesa
-
Málaga, Spania, 29010
- Hospital Regional Universitario de Malaga ? Hospital General
-
Seville, Spania, 41009
- Hospital Universitario Virgen Macarena
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spania, 08907
- Hospital Universitari de Bellvitge
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Spania, 28223
- Hospital Quiron de Madrid
-
-
Murcia
-
EL Palmar (EL Palmar), Murcia, Spania, 30120
- Hospital Universitario Virgen de Arrixaca
-
-
Pontevedra
-
Vigo, Pontevedra, Spania, 36213
- Hospital Alvaro Cunqueiro
-
-
-
-
-
Bern, Sveits, 3010
- Inselspital Bern Medizin Neurologie
-
Lugano, Sveits, 6903
- Ospedale Regionale di Lugano - Civico
-
-
-
-
-
Mannouba, Tunisia, 2010
- Hopital Razi
-
Monastir, Tunisia, 5000
- Fattouma Bourguiba Hospital
-
Sfax, Tunisia, 3029
- Hospital Habib Bourguiba
-
-
-
-
-
Berlin, Tyskland, 13347
- Jüdisches Krankenhaus Berlin
-
Böblingen, Tyskland, 71034
- Studienzentrum Dr. Bischof GmbH
-
Dresden, Tyskland, 01307
- Universitätsklinikum "Carl Gustav Carus", Zentrum für Klinische Neurowissenschaften
-
Giessen, Tyskland, 35385
- Universitätsklinikum Gießen und Marburg GmbH
-
Kiel, Tyskland, 24105
- Uniklinik Schleswig-Holstein
-
Stuttgart, Tyskland, 70174
- Praxis Dr. med. Andreas Kowalik, Arzt für Neurologie und Psychiatrie
-
Tübingen, Tyskland, 72076
- Universitätsklinikum Tübingen, Zentrum für Neurologie
-
Ulm, Tyskland, 89081
- Universitätsklinikum Ulm
-
Westerstede, Tyskland, 26655
- Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz
-
-
-
-
-
Dnipro, Ukraina, 49027
- SI USSRI of Medical and Social Problems of Disabilities of MOHU
-
Kharkiv, Ukraina, 61068
- Ams of Ukraine
-
Kyiv, Ukraina, 03037
- Medical Center of Private Execution First Private Clinic
-
Kyiv, Ukraina, 02123
- Medical Center Dopomoga Plus
-
Lviv, Ukraina, 79010
- Lviv Regional Clinical Hospital
-
Lviv, Ukraina, 79029
- "Neurofocus" LLC
-
Odesa, Ukraina, 65117
- Odesa Regional Clinical Hospital
-
Vinnytsi, Ukraina, 21009
- Medical Clinical Research Center of Medical Center LLC Health Clinic
-
Zaporizhzhya, Ukraina, 69600
- Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council
-
Zaporizhzhya, Ukraina, 69035
- LCC "Medical center "Unimed"
-
-
KIEV Governorate
-
Vinnytsia, KIEV Governorate, Ukraina, 21009
- Salutem Medical Center
-
-
Tavria Okruha
-
Dnipro, Tavria Okruha, Ukraina
- Separated structural unit ?University hospital? of Dnipro State Medical University
-
-
-
-
-
Budapest, Ungarn, 1033
- Clinexpert Kft.
-
Budapest, Ungarn, 1044
- S-Medicon Egeszsegugyi Szolgaltato Kft.
-
Eger, Ungarn, 3300
- Markhot Ferenc Oktatokorhaz és Rendelointezet
-
Kistarcsa, Ungarn, 2143
- Pest Megyei Flor Ferenc Korhaz
-
Szeged, Ungarn, 6725
- Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Expanded Disability Status Scale (EDSS) score of 0 - 5.5 at screening
- A diagnosis of RMS in accordance with the revised 2017 McDonald Criteria
- Ability to complete the 9-Hole Peg Test (9-HPT) for each hand in < 240 seconds
- Ability to perform the Timed 25-Foot Walk Test (T25FWT) in < 150 seconds
- For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs
- For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm
OLE Inclusion Criteria:
- Completed the DBT phase of the study (remaining on study treatment; no other disease-modifying therapy (DMT) administered) and who, in the opinion of the investigator, may benefit from treatment with fenebrutinib
- Participants randomized to the teriflunomide treatment arm during the DBT phase must undergo the accelerated teriflunomide elimination procedure (ATEP) prior to the first administration of open-label fenebrutinib
- For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs
- For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm
Exclusion Criteria:
- Disease duration of > 10 years from the onset of symptoms and an EDSS score at screening < 2.0
- Female participants who are pregnant or breastfeeding, or intending to become pregnant
- Male participants who intend to father a child during the study
- A diagnosis of primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (SPMS)
- Any known or suspected active infection at screening, including but not limited to a positive screening test for hepatitis B (HBV) and hepatitis C (HCV), an active or latent or inadequately treated infection with tuberculosis (TB), a confirmed or suspected progressive multifocal leukoencephalopathy (PML)
- History of cancer including hematologic malignancy and solid tumors within 10 years of screening
- Known presence of other neurological disorders, that could interfere with the diagnosis of MS or assessments of efficacy or safety during the study and clinically significant cardiovascular, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal (GI) disease
- Rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
- Hypoproteinemia
- Acute liver disease
- Chronic liver disease unless considered stable for > 6 months
- Presence of cirrhosis (Child-Pugh Class A, B, or C) or Gilbert's Syndrome
- Participants with significantly impaired bone marrow function or significant anemia, leukopenia, neutropenia or thrombocytopenia
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- History of alcohol or other drug abuse within 12 months prior to screening
- History of or currently active primary or secondary (non-drug-related) immunodeficiency, including known history of human immunodeficiency virus (HIV) infection
- Inability to complete an MRI scan
- Adrenocorticotropic hormone or systemic corticosteroid therapy within 4 weeks prior to screening (inhaled and topical corticosteroids are allowed)
- Receipt of a live-attenuated vaccine within 6 weeks prior to randomization
- Any previous treatment with immunomodulatory or immunosuppressive medication without an appropriate washout period
OLE Exclusion Criteria:
- Acute liver disease
- Chronic liver disease unless considered stable for > 6 months
- Cirrhosis (Child-Pugh Class A, B, or C)
- Gilbert's syndrome
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Fenebrutinib
Participants will receive oral (PO) fenebrutinib, with teriflunomide-matching placebo. |
Participants will receive fenebrutinib. Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo. |
|
Aktiv komparator: Teriflunomide
Participants will receive PO teriflunomide, with fenebrutinib-matching placebo in a blinded fashion. |
Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo. Participants will receive teriflunomide. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Annualisert tilbakefallsfrekvens (ARR)
Tidsramme: Minimum 96 uker
|
Minimum 96 uker
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Tid til utbruddet av sammensatt 12-ukers bekreftet funksjonshemmingsprogresjon (cCDP12)
Tidsramme: Minimum 96 uker
|
Minimum 96 uker
|
|
Tid til utbruddet av sammensatt 24-ukers bekreftet funksjonshemmingsprogresjon (cCDP24)
Tidsramme: Minimum 96 uker
|
Minimum 96 uker
|
|
Tid til utbruddet av 12 ukers bekreftet funksjonshemmingsprogresjon (CDP12)
Tidsramme: Minimum 96 uker
|
Minimum 96 uker
|
|
Tid til utbruddet av 24-ukers bekreftet funksjonshemmingsprogresjon (CDP24)
Tidsramme: Minimum 96 uker
|
Minimum 96 uker
|
|
Plasmakonsentrasjoner av Fenebrutinib ved spesifiserte tidspunkter
Tidsramme: Inntil 4,5 år
|
Inntil 4,5 år
|
|
Tid til begynnelse av sammensatt 12-ukers bekreftet progresjon uavhengig av tilbakefallaktivitet (CPIRA12)
Tidsramme: Minimum 96 uker
|
Minimum 96 uker
|
|
Prosentandel av deltakere med bivirkninger (AEs)
Tidsramme: Opptil 4,5 år
|
Opptil 4,5 år
|
|
Total Number of T1 Gadolinium Enhancing (Gd+) Lesions, New and/or Enlarging T2-weighted Lesions, as Detected by Magnetic Resonance Imaging (MRI)
Tidsramme: Baseline, Weeks 12, 24, 48 and 96
|
Baseline, Weeks 12, 24, 48 and 96
|
|
Percentage Change in Total Brain Volume From Week 24 as Assessed by MRI
Tidsramme: From Week 24 to Week 96
|
From Week 24 to Week 96
|
|
Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT) Score
Tidsramme: Minimum of 96 weeks
|
Minimum of 96 weeks
|
|
Change in Participant-reported Physical Impacts of Multiple Sclerosis (MS), as Measured by the Multiple Sclerosis Impact Scale (29-item), Version 2 (MSIS-29) Physical Scale
Tidsramme: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96
|
Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96
|
|
Percent Change From Baseline to Week 48 in the Concentration of Blood Neurofilament Light Chain (NfL)
Tidsramme: Baseline, Week 48
|
Baseline, Week 48
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Clinical Trials, Hoffmann-La Roche
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- GN41851
- 2019-004857-10 (EudraCT-nummer)
- 2019 (U.S. NIH-stipend/kontrakt)
- 2022-502609-14-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .